Market Research Logo

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2015

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2015’, provides an overview of the Metastatic Adenocarcinoma of The Pancreas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Metastatic Adenocarcinoma of The Pancreas Overview
Therapeutics Development
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Array BioPharma Inc.
Axcentua Pharmaceuticals AB
Biothera, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
CTI BioPharma Corp.
CytRx Corporation
Eleison Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Halozyme Therapeutics, Inc.
Incyte Corporation
MedImmune, LLC
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
NewLink Genetics Corporation
Novartis AG
Pfizer Inc.
Phoenix Biotechnology, Inc.
Sanofi
Targovax AS
Teva Pharmaceutical Industries Limited
Threshold Pharmaceuticals, Inc.
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AXP-10711 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-853520 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-37250 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRS-207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evofosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glufosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imprime PGG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-39110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indusatumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irinotecan sucrosofate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGK-974 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MesoCART - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel lipsomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-05204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEGPH-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tosedostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products
Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones
Featured News & Press Releases
Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
Nov 03, 2014: Threshold Pharmaceuticals' Partner Merck KGaA Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2015
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Biothera, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Halozyme Therapeutics, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by MedImmune, LLC, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Nanotherapeutics, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Sanofi, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax AS, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2015
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2015
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report